Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key

GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma

Showing 38 of 38 drug-target rows in SSL view, for TSG = SMC1A.

Drug	TSG	SLP (drug target)	#
olaparib	SMC1A	PARP1	1
olaparib	SMC1A	PARP2	1
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib	SMC1A	PIK3CA	3
alpelisib, everolimus, exemestane	SMC1A	PIK3CA	1
biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging	SMC1A	PIK3CA	1
biopsy, biospecimen collection, copanlisib, radiologic examination	SMC1A	PIK3CA	1
afatinib dimaleate	SMC1A	EGFR	7
alpelisib	SMC1A	PIK3CA	7
cetuximab	SMC1A	EGFR	7
copanlisib	SMC1A	PIK3CA	7
copanlisib hydrochloride	SMC1A	PIK3CA	7
erlotinib hydrochloride	SMC1A	EGFR	7
lapatinib	SMC1A	EGFR	7
lapatinib ditosylate	SMC1A	EGFR	7
necitumumab	SMC1A	EGFR	7
neratinib	SMC1A	EGFR	7
neratinib maleate	SMC1A	EGFR	7
niraparib	SMC1A	PARP1	7
niraparib	SMC1A	PARP2	7
niraparib tosylate	SMC1A	PARP1	7
niraparib tosylate	SMC1A	PARP2	7
osimertinib mesylate	SMC1A	EGFR	7
panitumumab	SMC1A	EGFR	7
regorafenib	SMC1A	EGFR	7
rucaparib	SMC1A	PARP1	7
rucaparib	SMC1A	PARP2	7
rucaparib camsylate	SMC1A	PARP1	7
rucaparib camsylate	SMC1A	PARP2	7
talazoparib	SMC1A	PARP1	7
talazoparib	SMC1A	PARP2	7
talazoparib tosylate	SMC1A	PARP1	7
talazoparib tosylate	SMC1A	PARP2	7
vandetanib	SMC1A	EGFR	7
afatinib	SMC1A	EGFR	2
dacomitinib	SMC1A	EGFR	2
erlotinib	SMC1A	EGFR	2
gefitinib	SMC1A	EGFR	2
osimertinib	SMC1A	EGFR	2

Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.